Elderberry for Influenza (Flu)
The evidence that elderberry treats influenza is weak and self-contradictory: a few small, dated, industry-linked trials suggested faster symptom relief, but the largest and most rigorous modern trial found no benefit. It should not be relied on to treat the flu.
Why this grade7-layer evidence engine
This claim earns a C (Weak Evidence), Disputed grade because the studies openly conflict. The positive flagship data, a 2004 RCT (PMID 15080016, n=60) reporting symptom relief about four days earlier, and a 2019 meta-analysis (PMID 30670267, n=180) claiming a large effect (Hedges g ~1.7), both rest on tiny, single-site, decades-old trials of the manufacturer-linked Sambucol product with poorly disclosed funding.
Decisively, the most recent and most rigorous trial, a 2020 double-blind placebo-controlled RCT (PMID 32929634, n=87), found no benefit (4.9 vs 5.3 days to improvement, p=0.57), and a post-hoc analysis hinted elderberry taken alone was about two days worse than placebo. The 2021 NIH-funded systematic review (PMID 33827515) rated overall certainty as low-to-very-low (GRADE), while reassuringly debunking the theoretical cytokine-storm worry.
Authorities reinforce the caution: the FDA treats elderberry only as a GRAS flavoring agent and has issued repeated warning letters against cold/flu claims, the WHO notes no controlled clinical data are available, and clinical bodies lean negative (Cleveland Clinic and specialty/CDC-IDSA guidance against it; Harvard Health cautious). For genuine influenza, vaccination and antiviral drugs remain the evidence-based choices.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.403
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status